腫瘍性ウイルス治療は,腫瘍内T細胞の浸透を促進し,抗PD-1免疫療法を改善する
Antoni Ribas1, Reinhard Dummer2, Igor Puzanov3
1University of California at Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
Cell
|September 9, 2017
まとめ
タリモゲンラヘルパレプベックとペンブロリズマブ (抗PD-1療法) を併用した腫瘍解消性ウイルス治療は,進行性メラノーマ患者で62%の客観的な応答率を示した. この組み合わせ療法により,T細胞の浸透が強化され,抗PD-1治療の有効性が改善される可能性があります.
科学分野:
- 腫瘍学
- 免疫学
- 臨床研究
背景:
- 先進的なメラノーマは依然として課題であり,新しい治療戦略が必要である.
- ペムブロリズマブ (抗PD-1) のような免疫チェックポイント阻害剤は治療に革命をもたらしましたが,反応率は異なります.
- 抗腫瘍免疫反応を強化するために,腫瘍ウイルスの研究が進められています.
研究 の 目的:
- 進行性メラノーマにおけるタリモゲン・ラハーパレプベックとペムブロリズマブの安全性と有効性を評価する.
- 腫瘍の微小環境と免疫細胞の浸透に対する腫瘍解毒性ウイルス治療の影響を調査する.
- 併用療法への反応に関連するバイオマーカーを調査する.
主な方法:
- 進行メラノーマ患者の21人を対象とした臨床試験.
- 治療はタリモゲンラヘルパレプベックとペンブロリズマブでした.
- 腫瘍生検は免疫細胞浸透 (CD8+ T細胞) と遺伝子/タンパク質発現 (PD- L1,IFN- γ) について分析された.
主要な成果:
- 疲労,発熱,寒さなど,一般的な副作用が認められた.
- 客観的な応答率は62%で,完全な応答率は33%であった.
- タリモゲンラハーパレプベック治療後のCD8+T細胞,PD- L1,IFN- γ発現が増加した.
- 免疫細胞の浸透は反応を予測できなかった.
結論:
- タリモゲン・ラハーパレプベックとペムブロリズマブは,進行したメラノーマに対する安全で効果的な組み合わせです.
- 腫瘍微環境を調節し,抗PD-1治療の有効性を高める可能性があります.
- 腫瘍免疫マーカーの変化は,腫瘍解毒性ウイルス治療の後,併用療法への反応を示唆する可能性があります.
関連する概念動画
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Cancer Vaccines
1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Cytotoxic T Cells-mediated Immune Response
7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K


